& Bouissane, L
Disclosures: Ken Liu: Nothing to Disclose, Simone Chin: Nothing to Disclose, Charlotte Kench: Nothing to Disclose, Rena Cao: Nothing to Disclose, Christina Lee: Nothing to Disclose, Claire West: Nothing to Disclose, Susan Virtue: Nothing to Disclose, Talal Valliani: Nothing to Disclose, David Bowen: Nothing to Disclose, Simone Strasser: Chiesi: Advisor, Roche Diagnostics: Advisor, Roche Therapeutics: Advisor, Norgine: Speaking and Teaching, Abbott Diagnostics: Advisor, CSL Behring: Advisor, Novo Nordisk: Advisor, Astra Zeneca: Advisor, Sirtex: Speaking and Teaching, Eisai: Speaking and Teaching, GEOFF McCaughan: Nothing to Disclose 1690 MORTALITY IMPROVEMENT IN CIRRHOTIC AND HEPATOCELLULAR CARCINOMA PATIENTS WITH MAJOR DISCREPANCIES ACCORDING TO ETIOLOGY: A 10-YEAR NATIONWIDE STUDY Claire DELACOTE 1 Xavier Lenne 2 Alexandre LOUVET 3 Line Ntandja Wandji 4 Amlie BRUANDET 5 Sylvie Deuffic-Burban 6 Philippe Mathurin 4 , 1 Inserm, CHU Lille, Universit de Lille, U1286 INFINITE, 2 CHU Lille, DIM, 3 CHU Lille, Hpital Claude Huriez, Service des maladies de l'appareil digestif, 4 CHU de Lille, Hpital Claude Huriez, Service des maladies de l'appareil digestif, 5 CHU de Lille, DIM, 6 Universit Paris Cit and Universit Sorbonne Paris Nord, Inserm, IAME Background: Use of direct antiviral agents (DAA), growing burden of metabolic syndrome (MS) and changes in alcohol per capita require to investigate evolution of mortality in patients with cirrhosis and / or hepatocellular carcinoma (HCC)
These brand-name drugs may be covered by insurance, unlike compounded semaglutide, and have also undergone rigorous clinical trials to prove their safety and effectiveness
Avoid repeated freezethaw cycles to maintain compound quality
In this study, we investigated the response of key metabolites and enzymes involved in the AsAGSH cycle of B
